COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02169336
Recruitment Status : Terminated (Lack of observed efficacy)
First Posted : June 23, 2014
Results First Posted : December 10, 2015
Last Update Posted : December 10, 2015
Lotus Clinical Research, LLC
Information provided by (Responsible Party):
Recro Pharma, Inc.

Brief Summary:
The primary objective of this study is to evaluate the analgesic efficacy of two dose levels of DEX-IN compared with placebo, using the summed pain intensity difference over the first 48 hours (SPID48) in subjects with acute moderate to severe pain following unilateral bunionectomy.

Condition or disease Intervention/treatment Phase
Pain, Post-operative Drug: Intranasal Dexmedetomidine Other: Intranasal Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 95 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy, Safety, and Pharmacokinetics of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy
Study Start Date : June 2014
Actual Primary Completion Date : September 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: DEX-IN 35mcg
DEX-IN 35mcg every 6 hours for 48 hours. DEX-IN 35mcg PRN for up to 3 additional days.
Drug: Intranasal Dexmedetomidine
Experimental: DEX-IN 50mcg
DEX-IN 50mcg every 6 hours for 48 hours. DEX-IN 50mcg PRN for up to 3 additional days.
Drug: Intranasal Dexmedetomidine
Placebo Comparator: IN Placebo
IN Placebo every 6 hours for 48 hours. IN Placebo PRN for up to 3 additional days.
Other: Intranasal Placebo

Primary Outcome Measures :
  1. Summed Pain Intensity Difference Over the First 48 Hours (SPID48). [ Time Frame: 48 hours ]
    Pain intensity was recorded using a Numeric Rating Scale (Range 0-10) where 0 equates to no pain, and 10 equates to the worst pain imaginable. Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours. Pain intensity differences from baseline at each time point were calculated and a time weighted SPID was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Voluntarily provide written informed consent.
  • Male or female between 18 and 70 years of age, inclusive.
  • Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair
  • Be American Society of Anesthesiology (ASA) physical class 1 or 2.
  • Female subject are eligible only if all the following apply:

    • Not pregnant;
    • Not lactating;
    • Not planning to become pregnant during the study;
    • Be surgically sterile; or at least two year post menopausal; or have a monogamous partner who is surgically sterile; or is practicing double-barrier contraception; or practicing abstinence; or using an insertable, injectable, transdermal, or combination oral contraceptive.
  • Male subjects must be surgically sterile or commit to the use of a reliable method of birth control
  • Have a body mass index ≤35 kg/m2
  • Be able to understand the study procedures, comply with all study procedures, and agree to participate in the study program.

Exclusion Criteria:

  • Have a known allergy to dexmedetomidine or any excipient DEX-IN/placebo or to any peri- or postoperative medications used in this study.
  • Have a clinically significant abnormal clinical laboratory tests value.
  • Have history of or positive test results for HIV, or hepatitis B or C.
  • Have a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, or other condition that would preclude participation in the study.
  • Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants.
  • Have another painful physical condition that may confound the assessments of post operative pain.
  • Have a history of syncope or other syncopal attacks.
  • Have evidence of a clinically significant 12 lead ECG abnormality.
  • Have a history of alcohol abuse (regularly drinks > 4 units of alcohol per day; 8 oz. beer, 3 oz. wine, 1 oz. spirits) or prescription/illicit drug abuse..
  • Have positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol abuse.
  • Have a history or evidence of orthostatic hypotension.
  • Have a resting heart rate of <50 beats per minutes or systolic blood pressure <100mmHg.
  • Have been receiving or have received chronic opioid therapy defined as greater than 15 morphine equivalents units per day for greater than 3 out of 7 days per week over a one-month period within 12 months.
  • Use concurrent therapy that could interfere with the evaluation of efficacy or safety, such as any drugs which in the investigator's opinion may exert significant analgesic properties or act synergistically with DEX-IN.
  • Unable to discontinue medications, that have not been at a stable dose for at least 14 days prior to the scheduled bunionectomy procedure, within 5 half lives of the specific prior medication (or, if half life is not known, within 48 hours) before dosing.
  • Have utilized any intranasal medications within the preceding 10 days.
  • Have signs or a history of significant rhinitis or rhinorrhea (constant or chronic), nasal polyps, mucosal lesions of the nostril, postnasal drip of any etiology (constant or chronic), nasal ulcers, septal perforation or deviation, any nasal surgery, anosmia, nasal piercings, or frequent nosebleeds or other nasal pathology, that is sufficient to interfere with IN drug delivery.
  • Have had an upper respiratory tract infection within 14 days of screening.
  • Have utilized corticosteroids, either systemically, inhalational either intranasally or oral, or by intra-articular injection, within 14 days prior to the study.
  • Have received any investigational product within 30 days before dosing with study medication.
  • Have previously received DEX-IN in clinical trials, or had bunionectomy in the last 3 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02169336

Layout table for location information
United States, California
Trovare Clinical Research, Inc.
Bakersfield, California, United States
Lotus Clinical Research, LLC
Pasadena, California, United States
United States, Texas
Endeavor Clinical Trials, P.A.
San Antonio, Texas, United States
Sponsors and Collaborators
Recro Pharma, Inc.
Lotus Clinical Research, LLC
Layout table for investigator information
Principal Investigator: Neil Singla, MD Lotus Clinical Research, LLC
Layout table for additonal information
Responsible Party: Recro Pharma, Inc. Identifier: NCT02169336    
Other Study ID Numbers: REC-13-012
First Posted: June 23, 2014    Key Record Dates
Results First Posted: December 10, 2015
Last Update Posted: December 10, 2015
Last Verified: November 2015
Keywords provided by Recro Pharma, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Neurologic Manifestations
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action